Analysts Initiate New Stock Ratings and Price Targets on These Healthcare Companies

Wall St. Watchdog reveals information about companies for which stock analysts initiated coverage in the Healthcare sector for the week ending December 9th, 2011.

  • Questcor Pharma (NASDAQ:QCOR): Ladenburg Thalmann initiated coverage of this company with a rating of Buy and a price target of $51 on Dec 5th. The shares recently traded at $44.03, up $0.83, or 1.92% since the analyst’s rating. About the company: Questcor Pharmaceuticals, Inc. develops and commercializes novel central nervous system-focused therapeutics that address significant unmet medical needs. The Company’s primary product is a natural source adrenocorticotropic hormone indicated for the treatment of acute exacerbations of multiple sclerosis, as well as a number of other conditions. Get the most recent company news and stock data here >>
  • Trius Therapeutics (NASDAQ:TSRX): Oppenheimer initiated coverage of this company with a rating of Outperform and a price target of $12 on Dec 5th. The shares recently traded at $7.01, down $0.2, or 2.77% since the analyst’s rating. About the company: Trius Therapeutics, Inc. is a biopharmaceutical company. The Company develops antibiotics for life threatening infections. Get the most recent company news and stock data here >>
  • Pharmacyclics (NASDAQ:PCYC): Rodman & Renshaw initiated coverage of this company with a rating of Mkt Outperform and a price target of $20 on Dec 7th. The shares recently traded at $12.65, down $2.34, or 15.61% since the analyst’s rating. About the company: Pharmacyclics, Inc. is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. The Company’s products are patented agents derived from its technology platform for designing and synthesizing energy-potentiating drugs. Get the most recent company news and stock data here >>
  • Amylin Pharma (NASDAQ:AMLN): Global Hunter Securities initiated coverage of this company with a rating of Accumulate and a price target of $14 on Dec 7th. The shares recently traded at $10.53, down $0.17, or 1.59% since the analyst’s rating. About the company: Amylin Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for diabetes and obesity. The Company’s marketed products include treatments for adults with type 1 and type 2 diabetes. Get the most recent company news and stock data here >>
  • Pluristem Therapeutics (NASDAQ:PSTI): Global Hunter Securities initiated coverage of this company with a rating of Speculative Buy and a price target of $5 on Dec 9th. The shares recently traded at $2.56, up $0.08, or 3.23% since the analyst’s rating. About the company: Pluristem Therapeutics, Inc. develops Messenchymal stem cell production technology and commercializes cell therapy products. The Company focuses on cell therapy to treat severe blood, cardiovascular, autoimmune, and other disorders. Get the most recent company news and stock data here >>
  • Curis (NASDAQ:CRIS): Oppenheimer initiated coverage of this company with a rating of Outperform and a price target of $6 on Dec 9th. The shares recently traded at $3.90, up $0.12, or 3.17% since the analyst’s rating. About the company: Curis, Inc. develops therapeutics for the regeneration and restoration of human tissues and organs. Get the most recent company news and stock data here >>
  • Synergetics (NASDAQ:SURG): Wunderlich initiated coverage of this company with a rating of Buy and a price target of $8 on Dec 9th. About the company: Synergetics USA, Inc. develops and manufactures medical devices and products for the hospital and healthcare communities. The Company’s products include bipolar electrosurgical generators and disposable and non-disposable medical products. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>